-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dilanubicel in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dilanubicel in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dilanubicel in Acute Lymphocytic Leukemia (ALL,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dilanubicel in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dilanubicel in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dilanubicel in Chronic Myelocytic Leukemia (CML,...
-
Product Insights
Hematopoietic Stem Cell Transplantation – Drugs In Development, 2023
Global Markets Direct’s, ‘Hematopoietic Stem Cell Transplantation - Drugs In Development, 2023’, provides an overview of the Hematopoietic Stem Cell Transplantation pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hematopoietic Stem Cell Transplantation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Drugs In Development, 2023’, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DVX-201 in Refractory Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DVX-201 in Refractory Acute Myeloid Leukemia Drug Details: DVX-201 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DVX-201 in Relapsed Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DVX-201 in Relapsed Acute Myeloid Leukemia Drug Details: DVX-201 is under development for the treatment...
-
Product Insights
Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Ovarian Cancer Pipeline Drugs Market Overview Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, and changes in bowel habits, such as constipation, loss of appetite, and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy, and radiation therapy....